| Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. | |
| | |
MedLine Citation:
|
PMID: 19279474 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: TNF-alpha is a critical mediator of inflammation with an important role in metabolic profile and insulin resistance. The regulation of these parameters by TNF-alpha in inflammatory bowel disease (IBD) is, however, poorly understood. The aim of this study was to assess the in-vivo TNF-alpha-mediated regulation of insulin resistance and of lipid levels in patients with IBD. METHODS: Twenty-two patients with IBD (eight females; 19 Crohn's disease) received infliximab according to treating physician's assessment at weeks 0, 2 and 6 from baseline and subsequently every 8 weeks and were prospectively followed for 14 weeks. Fasting insulin, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, apolipoprotein A1 (apo-A1), apolipoprotein B100 and lipoprotein a were measured in serum at baseline and at week 14. Insulin resistance was calculated with the use of the Homeostasis Model Assessment index. RESULTS: Infliximab therapy induced clinical response or remission in 19 of the 22 patients. C-reactive protein levels were significantly decreased by week 14. Body mass index was increased in all patients. No difference was observed in insulin levels, Homeostasis Model Assessment index, triglycerides, LDL cholesterol, apolipoprotein B100 and lipoprotein a. In contrast, total cholesterol, HDL cholesterol and apo-A1 levels were significantly increased from baseline. CONCLUSION: TNF-alpha inhibition does not alter insulin resistance in IBD patients. In contrast, total cholesterol, HDL cholesterol and apo-A1 levels are significantly increased after infliximab treatment compared with baseline. The importance of these alterations needs to be clarified in future studies. |
| | |
Authors:
|
Ioannis E Koutroubakis; Pantelis Oustamanolakis; Niki Malliaraki; Konstantinos Karmiris; Ioannis Chalkiadakis; Emmanouel Ganotakis; Nikolaos Karkavitsas; Elias A Kouroumalis |
Related Documents
:
|
6848894 - Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized,... 19804794 - Impact of progressive resistance training on lipids and lipoproteins in adults: another... 17056204 - Hypolipemic effect of water extracts of picrorrhiza kurroa in high fat diet treated mouse. 8374254 - Changes of serum lipid patterns during long-term anticonvulsive treatment. 18708594 - Effect of diet containing phytate and phytase on the activity and messenger ribonucleic... 6876764 - Serum lipoproteins in lepromatous leprosy. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 21 ISSN: 1473-5687 ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-03-12 Completed Date: 2010-02-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 283-8 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, University Hospital Heraklion, Heraklion, Crete, Greece. ikoutroub@med.uoc.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / pharmacology*, therapeutic use Apolipoprotein A-I / blood C-Reactive Protein / metabolism Cholesterol / blood Female Follow-Up Studies Gastrointestinal Agents / pharmacology*, therapeutic use Humans Inflammatory Bowel Diseases / blood*, drug therapy, physiopathology Insulin Resistance / physiology* Lipid Metabolism / drug effects* Male Prospective Studies Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Apolipoprotein A-I; 0/Gastrointestinal Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 57-88-5/Cholesterol; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein i...
Next Document: Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survi...